Acute reversible neurological deficit following intrathecal chemotherapy
- PMID: 1998991
- DOI: 10.1007/BF00685121
Acute reversible neurological deficit following intrathecal chemotherapy
Abstract
We report on two patients with non-Hodgkin's lymphoma (NHL) who developed reversible, short-lived neurological deficit following intrathecal (i.t.) chemotherapy. One patient received i.t. methotrexate for treatment of meningeal disease, and the other received i.t. methotrexate with cytosine arabinoside (ara-C) and hydrocortisone as central nervous system (CNS) prophylaxis. Although transient paresis following i.t. chemotherapy has previously been reported, it has been attributed to the preservatives contained in the diluents. Our two patients, however, received preservative-free solutions.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical